← Back to Clinical Trials
Recruiting NCT07551440

NCT07551440 Identification of Therapeutic Targets in Metastatic Gastric Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07551440
Status Recruiting
Phase
Sponsor Chinese University of Hong Kong
Condition Stomach Neoplasms, Benign
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2023-10-15
Primary Completion 2033-04

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2023-10-15 with a primary completion date of 2033-04.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This is a pilot study aiming at identifying novel therapeutic molecular targets in patients with gastric cancer with lymph nodes or distant metastasis. All patients who are diagnosed with gastric cancer with metastases in the Prince of Wales Hospital will be screened for eligibility.

Eligibility Criteria

Inclusion Criteria: 1. Patients age \>= 18, \<= 80 years old 2. Performance status (WHO) \<=2 3. Gastric adenocarcinoma with lymph node metastasis or distant metastasis such as liver metastases, lung metastases, bone metastases, peritoneum metastases 4. Patients with isolated ovarian metastasis could be included 5. Patients who will be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 6. Ability to give written consent before the commencement of treatment Exclusion Criteria: 1. Patient who will not be undergoing neoadjuvant chemotherapy/ target therapy/ immunotherapy or palliative chemotherapy/ target therapy/ immunotherapy 2. Pregnancy or breastfeeding 3. Patients with irreversible coagulation disorders

Contact & Investigator

Central Contact

Shannon Melissa Chan, PhD

✉ shannonchan@surgery.cuhk.edu.hk

📞 35052627

Frequently Asked Questions

Who can join the NCT07551440 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Stomach Neoplasms, Benign. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07551440 currently recruiting?

Yes, NCT07551440 is actively recruiting participants. Contact the research team at shannonchan@surgery.cuhk.edu.hk for enrollment information.

Where is the NCT07551440 trial being conducted?

This trial is being conducted at Hong Kong, Hong Kong.

Who is sponsoring the NCT07551440 clinical trial?

NCT07551440 is sponsored by Chinese University of Hong Kong. The trial plans to enroll 100 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology